156 related articles for article (PubMed ID: 32104551)
1. Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale.
Kaiser K; Lyleroehr M; Shaunfield S; Lacson L; Corona M; Kircher S; Nittve M; Cella D
World J Gastrointest Oncol; 2020 Feb; 12(2):205-218. PubMed ID: 32104551
[TBL] [Abstract][Full Text] [Related]
2. Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial.
Aoyama T; Morita S; Kono T; Hata T; Mishima H; Sakamoto J
J Cancer Res Ther; 2021; 17(6):1473-1478. PubMed ID: 34916380
[TBL] [Abstract][Full Text] [Related]
3. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
5. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
[TBL] [Abstract][Full Text] [Related]
6. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.
Calhoun EA; Welshman EE; Chang CH; Lurain JR; Fishman DA; Hunt TL; Cella D
Int J Gynecol Cancer; 2003; 13(6):741-8. PubMed ID: 14675309
[TBL] [Abstract][Full Text] [Related]
7. Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
Zhi WI; Ingram E; Li SQ; Chen P; Piulson L; Bao T
Integr Cancer Ther; 2018 Dec; 17(4):1079-1086. PubMed ID: 30027756
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial.
Rokhsareh S; Haghighi S; Tavakoli-Ardakani M
J Oncol Pharm Pract; 2023 Jan; 29(1):60-65. PubMed ID: 34738855
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy.
Beijers A; Mols F; Dercksen W; Driessen C; Vreugdenhil G
J Community Support Oncol; 2014 Nov; 12(11):401-6. PubMed ID: 25856013
[TBL] [Abstract][Full Text] [Related]
11. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
Teng C; ; Blinman PL; Vardy JL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
[TBL] [Abstract][Full Text] [Related]
13. Validation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Questionnaire for the Latin American Population.
Ribeiro IL; Lorca LA; Cuevas-Cid R; Dixit S; Yáñez-Benavides N; Ortega-Gonzalez F
Int J Breast Cancer; 2022; 2022():6533797. PubMed ID: 36124163
[TBL] [Abstract][Full Text] [Related]
14. Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.
Timmins HC; Li T; Trinh T; Kiernan MC; Harrison M; Boyle F; Friedlander M; Goldstein D; Park SB
Oncologist; 2021 May; 26(5):366-374. PubMed ID: 33523545
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
[TBL] [Abstract][Full Text] [Related]
16. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
Anastasio MK; Unnithan S; Scott A; Hayes T; Shah S; Moss HA; Erkanli A; Havrilesky LJ
Obstet Gynecol; 2023 Dec; 142(6):1459-1467. PubMed ID: 37883997
[TBL] [Abstract][Full Text] [Related]
17. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.
Mols F; Beijers T; Lemmens V; van den Hurk CJ; Vreugdenhil G; van de Poll-Franse LV
J Clin Oncol; 2013 Jul; 31(21):2699-707. PubMed ID: 23775951
[TBL] [Abstract][Full Text] [Related]
19. Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial.
Trinh T; Park SB; Murray J; Pickering H; Lin CS; Martin A; Friedlander M; Kiernan MC; Goldstein D; Krishnan AV
Support Care Cancer; 2021 Feb; 29(2):1103-1110. PubMed ID: 32607598
[TBL] [Abstract][Full Text] [Related]
20. Peripheral neuropathy exacerbated by lenalidomide in a patient with multiple myeloma.
Kamimura T; Miyamoto T; Yokota N; Aoki T; Ito Y; Akashi K
Intern Med; 2014; 53(15):1651-3. PubMed ID: 25088880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
